DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Bioequivalence of a new tablet formulation of sotalol hydrochloride in comparison to a standard preparations]

Author(s): Herrmann R, Kleinbloesem CH

Affiliation(s): Dr. Rentschler Arzneimittel GmbH & Co, Abteilung Analytische Entwicklung/Biopharmazie, Laupheim.

Publication date & source: 1994-05, Arzneimittelforschung., 44(5):589-92.

Publication type: Clinical Trial; Comparative Study ; English Abstract; Randomized Controlled Trial

Bioequivalence of a New Sotalol Hydrochloride Tablet Formulation Compared with a Standard Preparation An investigation on the bioavailability of a new tablet with 80 mg sotalol hydrochloride (Rentibloc mite, CAS 959-24-0) was performed in a two-way cross-over study with 16 persons. The relative bioavailability with respect to a reference preparation for AUC0-infinity was 101.9% and for Cmax 104.5%. A positive decision for bioequivalence derived from the usual confidence intervals for both parameters. The difference in tmax showed no clinical relevance. The new formulation is bioequivalent to the reference.

Page last updated: 2007-05-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017